Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.58 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.45 |
| ▸ | EP300 | Q09472 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | USP1 | O94782 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844289 | 0.91 | BRD4 (0.56) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL17798129 | 0.90 | BRD4 (0.72) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL16347921 | 0.89 | BRD4 (0.58) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL17860624 | 0.88 | BRD4 (0.57) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL17798166 | 0.88 | BRD4 (0.57) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL29920772 | 0.88 | BRD4 (0.57) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL29920722 | 0.87 | BRD4 (0.58) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL17797964 | 0.87 | BRD4 (0.58) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL17798093 | 0.86 | BRD4 (0.55) | BRD4CREBBPEP300PDE10A | |
| SCHEMBL17865323 | 0.86 | BRD4 (0.56) | BRD4CREBBPEP300PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10231953-B2 | Inhibitors of bromodomains | ZENITH EPIGENETICS LTD. (CA) | 2019-03-19 | — | — | US | disclosed |
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| WO-2016097863-A1 | INHIBITORS OF BROMODOMAINS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360760-A1 | Inhibitors of Bromodomains | BRDT, BRD3, BRPF3 | BRD4 5/4885CREBBP 43/4885EP300 13/4885 |
| US-10231953-B2 | Inhibitors of bromodomains | BRDT, BRD3, BRPF3 | BRD4 5/4885CREBBP 43/4885EP300 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.